Out-of-pocket costs of biologic treatments for chronic rhinosinusitis with nasal polyposis in the Medicare population

Int Forum Allergy Rhinol. 2022 Oct;12(10):1295-1298. doi: 10.1002/alr.22976. Epub 2022 Jan 27.
No abstract available

Keywords: Medicare Part D; chronic rhinosinusitis; dupilumab; mepolizumab; nasal polyposis; omalizumab; out-of-pocket.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Biological Products*
  • Chronic Disease
  • Health Expenditures
  • Humans
  • Medicare
  • Nasal Polyps* / drug therapy
  • Nasal Polyps* / epidemiology
  • Rhinitis* / drug therapy
  • Sinusitis* / drug therapy
  • United States / epidemiology

Substances

  • Biological Products